Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte Names New Board Of Director
Dr Dixon’s prior experience include 30 years in the biopharmaceutical industry involving multiple product launches and new drug approvals across a broad range of therapeutic areas and the
Dr Dixon’s prior experience include 30 years in the biopharmaceutical industry involving multiple product launches and new drug approvals across a broad range of therapeutic areas and the
So far COQ10 products were available mostly as soft-gel capsules or as tablets. Elder said that its R&D centre worked extensively on the development of a chewable form
Mylan claimed that for patients in whom the drug is used for more than 2-3 weeks, periodic reevaluation is recommended to determine whether there is a continuing need.
Shrink claimed that utilising its rapid prototyping solutions, three dimensional biochips can be developed with precise specifications compared to current production methods that require many hours, day or
Nippon Boehringer Ingelheim and Astellas said that they are committed to further contribute to the treatment of hypertension by further enhancing the promotion of the Micardis family. Micardis
Watson’s Sevelamer carbonate tablet is the generic version of Genzyme’s Renvela, a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease who
RoundTable has committed to support Renaissance Pharma with the full resources of the firm including substantial investment capital. RoundTable said that Mr Frechette brings experience to Renaissance Pharma
The fluidization of powders, using compressed air through a porous media to make flow like liquids, is a process used in many industries. Applications for powder fluidization are
HealthSport and SMI Manufacturing said that the merger is expected to result in a company into developing and producing oral thin film for the delivery of dietary supplements
Following entry into toxicological studies and clinical Phases I to III, Cevec is expected to receive undisclosed milestone payments after market approval. Cevec claimed that the transient CAP-T